Patents-Review.com
🔗 Permalink
Inventor profile of:

John C. Williams

City:

Monrovia, California

Country:

United States

Published Applications:

32

Last publication date:

2026-01-08

Top Assignees for applications by John C. Williams

The entities that hold a legal rights for patent applications filed by inventor Williams John C.:

Recent patent applications by Williams John C.

John C. Williams from Monrovia, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-01-08
US20260008864A1
Chemistry; metallurgy

BISPECIFIC ANTI-CD38-CD3 BINDERS

 #2 | 2025-02-27
US20250066418A1
Chemistry; metallurgy

CYSTEINE PEPTIDE-ENABLED ANTIBODIES

 #3 | 2025-01-09
US20250011465A1
Chemistry; metallurgy

MULTI-SPECIFIC LIGAND BINDERS

 #4 | 2024-12-05
US20240400686A1
Chemistry; metallurgy

ANTI-CD3 ANTIBODIES AND USES THEREOF

 #5 | 2024-09-26
US20240317873A1
Chemistry; metallurgy

ANTI-HVEM ANTIBODIES

 #6 | 2024-06-27
US20240207393A1
Human necessities

Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy

 #7 | 2023-12-07
US20230391887A1
Chemistry; metallurgy

MULTIVALENT MEDITOPES, MEDITOPE-BINDING ANTIBODIES AND USES THEREOF

 #8 | 2023-05-11
US20230141575A1
Chemistry; metallurgy

MULTIVALENT CHEMOKINE RECEPTOR BINDING COMPLEXES

 #9 | 2023-03-16
US20230085485A1
Human necessities

DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS

 #10 | 2022-03-24
US20220089642A1
Chemistry; metallurgy

Fc Receptor-ACE2 Conjugates and Use Thereof

 #11 | 2022-03-03
US20220062410A1
Human necessities

Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy

 #12 | 2021-03-04
US20210061922A1
Chemistry; metallurgy

Multi-specific ligand binders

 #13 | 2021-03-04
US20210061879A1
Chemistry; metallurgy

MEDITOPE-ENABLED T CELLS

 #14 | 2020-11-26
US20200368364A1
Human necessities

CYSTEINE PEPTIDE-ENABLED ANTIBODIES

 #15 | 2020-10-15
US20200325212A1
Chemistry; metallurgy

Tumor-selective CTLA-4 antagonists

 #16 | 2020-09-03
US20200277400A1
Chemistry; metallurgy

CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS

 #17 | 2020-05-28
US20200164077A1
Human necessities

Development of masked therapeutic antibodies to limit off-target effects

 #18 | 2020-02-20
US20200054736A1
Human necessities

Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy

 #19 | 2018-08-02
US20180215806A1
Chemistry; metallurgy

Tumor-selective CTLA-4 antagonists

 #20 | 2018-05-31
US20180148514A1
Chemistry; metallurgy

MULTIVALENT MEDITOPES, MEDITOPE-BINDING ANTIBODIES AND USES THEREOF

 #21 | 2017-08-10
US20170226223A1
Chemistry; metallurgy

Chimeric antigen receptor compositions

 #22 | 2017-08-03
US20170218074A1
Chemistry; metallurgy

Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies

 #23 | 2016-11-17
US20160333114A1
Chemistry; metallurgy

Chimeric antigen receptor compositions

 #24 | 2016-06-02
US20160152711A1
Chemistry; metallurgy

DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS: APPLICATION TO ANTI-EGFR ANTIBODIES

 #25 | 2016-05-26
US20160144042A1
Human necessities

Development of masked therapeutic antibodies to limit off-target effects

 #26 | 2015-01-29
US20150030535A1
Chemistry; metallurgy

Meditopes and meditope-binding antibodies and uses thereof

 #27 | 2014-04-24
US20140113348A1
Chemistry; metallurgy

Meditopes and meditope-binding antibodies and uses thereof

 #28 | 2013-06-13
US20130150558A1
Chemistry; metallurgy

Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies

 #29 | 2013-03-07
US20130060010A1
Human necessities

Development of masked therapeutic antibodies to limit off-target effects

 #30 | 2012-11-29
US20120301400A1
Human necessities

Meditopes and meditope-binding antibodies and uses thereof

 #31 | 2012-07-12
US20120177568A1
Chemistry; metallurgy

Meditopes and related meditope-monoclonal antibody delivery systems, synthesis and therapeutic uses thereof

 #32 | 2011-07-21
US20110178279A1
Chemistry; metallurgy

DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS: APPLICATION TO ANTI-EGFR ANTIBODIES
InventorID:

129473 ⎘